Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Rohini Beavon"'
Autor:
Myron J. Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Kiazand, Mark T. Esser
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 6, Pp 1253-1268 (2024)
Abstract Introduction The phase 3 PROVENT and STORM CHASER studies evaluated AZD7442 (tixagevimab/cilgavimab) for pre-exposure and post-exposure prophylaxis of symptomatic coronavirus disease 2019 (COVID-19). We report the final 15-month results of b
Externí odkaz:
https://doaj.org/article/a0dc96dc6a4541d2935ee2e82a120a9f
Autor:
Karin Hansen, Elisabeth Rünow, Gustav Torisson, Christian Theilacker, Andreas Palmborg, Kaijie Pan, Qin Jiang, Jo Southern, Rohini Beavon, Bradford D. Gessner, Kristian Riesbeck, Jonas Ahl
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
ObjectivesIn Sweden, pneumococcal serotype distribution in adults with community-acquired pneumonia (CAP) and potential coverage of currently licensed pneumococcal conjugate vaccines (PCVs) is unknown.MethodsDuring 2016–2018, patients aged ≥18 ye
Externí odkaz:
https://doaj.org/article/1d7955b0a8124a169384fa8254586972
Autor:
Claire von Mollendorf, Mukhchuluun Ulziibayar, Bradford D. Gessner, Lien Anh Ha Do, Cattram D. Nguyen, Rohini Beavon, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Adam Jenney, Eileen M. Dunne, Catherine Satzke, Badarchiin Darmaa, Tuya Mungun, E. Kim Mulholland
Publikováno v:
BMC Public Health, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colo
Externí odkaz:
https://doaj.org/article/1eaff1b28fcb4da8a6c901126368c6c5
Autor:
Adamantia Liapikou, Athanasios Konstantinidis, Vasiliki Kossyvaki, John Skiadas, Damianos Menegas, Cristina Méndez, Rohini Beavon, Elizabeth Begier, Bradford D. Gessner, Haralampos Milionis, Vasilios Tsimihodimos, Gerasimos Baxevanos, Theodora Argiriadou, Chrysavgi Terrovitou, Michael Toumbis, The EGNATIA Study Group
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Greece introduced a 13-valent pneumococcal conjugate vaccine (PCV13) into the infant national immunization program in 2010 (3 + 1 schedule until June 2019). Since 2015, PCV13 has been recommended for adults aged 19–64 years with comorbidities and a
Externí odkaz:
https://doaj.org/article/ca08f7af03774d50ad3c1c20eb075a50
Autor:
Elena Mitsi, Jesús Reiné, Britta C. Urban, Carla Solórzano, Elissavet Nikolaou, Angela D. Hyder-Wright, Sherin Pojar, Ashleigh Howard, Lisa Hitchins, Sharon Glynn, Madlen C. Farrar, Konstantinos Liatsikos, Andrea M. Collins, Naomi F. Walker, Helen C. Hill, Esther L. German, Katerina S. Cheliotis, Rachel L. Byrne, Christopher T. Williams, Ana I. Cubas-Atienzar, Tom E. Fletcher, Emily R. Adams, Simon J. Draper, David Pulido, Rohini Beavon, Christian Theilacker, Elizabeth Begier, Luis Jodar, Bradford D. Gessner, Daniela M. Ferreira
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 7 (2022)
Background Although recent epidemiological data suggest that pneumococci may contribute to the risk of SARS-CoV-2 disease, cases of coinfection with Streptococcus pneumoniae in patients with coronavirus disease 2019 (COVID-19) during hospitalization
Externí odkaz:
https://doaj.org/article/b2d172fcc22a4eafaa71e455bedd326d
Autor:
Andrea Orsi, Alexander Domnich, Stefano Mosca, Matilde Ogliastro, Laura Sticchi, Rosa Prato, Francesca Fortunato, Domenico Martinelli, Fabio Tramuto, Claudio Costantino, Vincenzo Restivo, Vincenzo Baldo, Tatjana Baldovin, Elizabeth Begier, Christian Theilacker, Eva Agostina Montuori, Rohini Beavon, Bradford Gessner, Giancarlo Icardi
Publikováno v:
Microorganisms, Vol 11, Iss 1, p 70 (2022)
Pneumococcal community-acquired pneumonia (CAP) is a leading cause of mortality. Following the introduction of pneumococcal conjugate vaccines (PCVs) in children, a decrease in the burden of the disease was reported. In parallel, an increase in non-v
Externí odkaz:
https://doaj.org/article/0daca8281cf04e4abb611c354210da3a
Autor:
John Njuma Libwea, Mark A Fletcher, Paul Koki Ndombo, Angeline Boula, Nadesh Taku Ashukem, Madeleine Ngo Baleba, Rachel Sandrine Kingue Bebey, Eric Gaston Nkolo Mviena, Jean Tageube, Marie Kobela Mbollo, Sinata Koulla-Shiro, Shabir Madhi, Berthe-Marie Njanpop-Lafourcade, Ali Mohammad, Elizabeth Begier, Joanna Southern, Rohini Beavon, Bradford Gessner
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0250010 (2021)
BackgroundThe 13-valent pneumococcal conjugate vaccine (PCV13) entered Cameroon's childhood national immunization programme (NIP) in July 2011 under a 3-dose schedule (6, 10, 14 weeks of age) without any catch-up. We described the impact of PCV13 ons
Externí odkaz:
https://doaj.org/article/0407f38b1a8545e0ab29d07310b34d2a
Autor:
Rohini Beavon, Dashtseren Luvsantseren, E. Kim Mulholland, Badarchiin Darmaa, Adam Jenney, Catherine Satzke, Cattram D. Nguyen, Eileen M. Dunne, Bujinlkham Suuri, Mukhchuluun Ulziibayar, Claire von Mollendorf, Lien Anh Ha Do, Tuya Mungun, Bradford D Gessner, Dorj Narangerel
Publikováno v:
BMC Public Health, Vol 21, Iss 1, Pp 1-13 (2021)
Background Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colonisation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::151db5da2a92d38b61d576f6d0907f4c
https://doaj.org/article/1eaff1b28fcb4da8a6c901126368c6c5
https://doaj.org/article/1eaff1b28fcb4da8a6c901126368c6c5
Autor:
Ryan E. Robinson, Elena Mitsi, Elissavet Nikolaou, Sherin Pojar, Tao Chen, Jesús Reiné, Tinashe K. Nyazika, James Court, Kelly Davies, Madlen Farrar, Patricia Gonzalez-Dias, Josh Hamilton, Helen Hill, Lisa Hitchins, Ashleigh Howard, Angela Hyder-Wright, Maia Lesosky, Konstantinos Liatsikos, Agnes Matope, Daniella McLenaghan, Christopher Myerscough, Annabel Murphy, Carla Solórzano, Duolao Wang, Hassan Burhan, Manish Gautam, Elizabeth Begier, Christian Theilacker, Rohini Beavon, Annaliesa S. Anderson, Bradford D. Gessner, Stephen B. Gordon, Andrea M. Collins, Daniela M. Ferreira
Publikováno v:
American journal of respiratory and critical care medicine
RationaleStreptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programmes, SPN3 declines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95314b4c69b4f8502a2b5b2f34b0db69
https://pubmed.ncbi.nlm.nih.gov/35856830
https://pubmed.ncbi.nlm.nih.gov/35856830
Autor:
Myron J, Levin, Andrew, Ustianowski, Steven, Thomas, Alison, Templeton, Yuan, Yuan, Seth, Seegobin, Catherine F, Houlihan, Ibrahim, Menendez-Perez, Simon, Pollett, Rosalinda H, Arends, Rohini, Beavon, Kanika, Dey, Pedro, Garbes, Elizabeth J, Kelly, Gavin C K W, Koh, Stefan, Ivanov, Karen A, Near, Audrey, Sharbaugh, Katie, Streicher, Menelas N, Pangalos, Mark T, Esser
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).Adults without prior SARS-CoV-2 infection or COVID-19 vaccination were enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd225abf1d88ca0fbc99cf191830b419
https://pubmed.ncbi.nlm.nih.gov/36411267
https://pubmed.ncbi.nlm.nih.gov/36411267